StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3080% above fair value
$276.32+10.15 (+3.81%)

Close on Nov 4, 2026Market cap $665.90BP/E 41.9Yield 1.86%

Johnson & Johnson Other Pulmonary Hypertension medicines by Quarter

Other Pulmonary Hypertension medicines — International sales ($M) ($M)

QuarterlyAnnual

Johnson & Johnson Other Pulmonary Hypertension medicines: $30M in Q3 2026, down 23.1% from a year earlier.

Latest, Q3 2026
30
Period ended Sep 30, 2026
Change on a year earlier
-23.1%
39 in Q3 2025
History
39 quarters
Since Q1 2017
Sources
31
Documents cited below

Where the Q3 2026 figure comes from

Source: Form 10-Q (filed 2026-10-21) ↗

Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Pulmonary Hypertension medicines — International sales ($M) ($M)Year on yearSource
Q3 2026Sep 30, 202630-23.1%Form 10-Q (filed 2026-10-21) ↗
Q2 2026Jun 28, 202634-15.0%Form 10-Q (filed 2026-07-23) ↗
Q1 2026Mar 29, 202634-8.1%Form 10-Q (filed 2026-04-22) ↗
Q4 2025Dec 28, 202539+2.6%Form 10-K (filed 2026-02-11) ↗
Q3 2025Sep 28, 2025390.0%Form 10-Q (filed 2026-10-21) ↗
Q2 2025Jun 29, 202540-18.4%Form 10-Q (filed 2026-07-23) ↗
Q1 2025Mar 30, 202537-5.1%Form 10-Q (filed 2026-04-22) ↗
Q4 2024Dec 29, 202438-15.6%Form 10-K (filed 2026-02-11) ↗
Q3 2024Sep 29, 202439-7.1%Form 10-Q (filed 2025-10-22) ↗
Q2 2024Jun 30, 202449+2.1%Form 10-Q (filed 2025-07-24) ↗
Q1 2024Mar 31, 202439-17.0%Form 10-Q (filed 2025-04-23) ↗
Q4 2023Dec 31, 202345-6.2%Form 10-K (filed 2026-02-11) ↗
Q3 2023Oct 1, 202342-8.7%Form 10-Q (filed 2024-10-23) ↗
Q2 2023Jul 2, 202348-12.7%Form 10-Q (filed 2024-07-25) ↗
Q1 2023Apr 2, 202347-11.3%Form 10-Q (filed 2024-05-01) ↗
Q4 2022Jan 1, 202348-14.3%Form 10-K (filed 2025-02-13) ↗

Breakdown

What makes up other Pulmonary Hypertension medicines

Cite this data

StockData. (2026). Johnson & Johnson Other Pulmonary Hypertension medicines ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-other-ph-intl

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.

See a number that looks wrong?